fingolimod hydrochloride has been researched along with Chemical and Drug Induced Liver Injury in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, B; He, X; Kang, K; Pan, D; Sun, Y | 1 |
| Décard, BF; Derfuss, T; Diebold, M; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Tsagkas, C | 1 |
| Ataei, S; Ghiasian, M; Mohammadi, Y; Nafisi, H; Ranjbar, A | 1 |
| Bi, Y; Chen, W; Chu, Y; Liu, G; Liu, H; Lu, Y; Wang, R; Wang, X; Yang, H; Yang, R; Zhang, Y; Zhang, Z | 1 |
| Memon, A; Miranda, J | 1 |
| Antel, J; Bar-Or, A; Haegert, DG; Johnson, TA; Keezer, M; Lapierre, Y; Shames, I | 1 |
| Chun, J; Cohen, JA | 1 |
| Baum, K; Björnsson, ES; Chen, EY; Collins, W; Lee, WM; Löve, A; Merz, M; Olafsson, S | 1 |
| Kaneko, T; Kawana, H; Kobayashi, E; Murakami, T; Takahashi, M; Yasue, T | 1 |
1 review(s) available for fingolimod hydrochloride and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Topics: Animals; Central Nervous System; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Heart Diseases; Humans; Immunosuppressive Agents; Infections; Liver Diseases; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Respiration Disorders; Sphingosine | 2011 |
2 trial(s) available for fingolimod hydrochloride and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing-remitting multiple sclerosis: A clinical trial study.
Topics: Adult; Antioxidants; Chemical and Drug Induced Liver Injury; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Liver; Male; Middle Aged; Multiple Sclerosis; Recurrence; Silymarin | 2021 |
Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
Topics: Adult; CD8-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Count; Lymphocytes; Lymphopenia; Mediastinum; Middle Aged; Multiple Sclerosis; Patient Dropouts; Propylene Glycols; Receptors, CCR7; Sphingosine; Withholding Treatment | 2010 |
6 other study(ies) available for fingolimod hydrochloride and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
FTY720 attenuates APAP‑induced liver injury via the JAK2/STAT3 signaling pathway.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Fingolimod Hydrochloride; Male; Mice; Mice, Inbred C57BL; Signal Transduction | 2022 |
Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.
Topics: Administration, Oral; Adult; Chemical and Drug Induced Liver Injury; Demyelinating Diseases; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2019 |
Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells.
Topics: Animals; CD11b Antigen; Cell Differentiation; Cells, Cultured; Chemical and Drug Induced Liver Injury; Female; Fingolimod Hydrochloride; Immunoblotting; Immunosuppressive Agents; Liver; Male; Mice; Mice, Inbred C57BL; Myeloid Cells; Nitric Oxide; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Propylene Glycols; Receptors, Chemokine; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sirolimus; Sphingosine; T-Lymphocytes, Regulatory; Th1 Cells; TOR Serine-Threonine Kinases | 2014 |
Hepatitis E virus infection in a patient with suspected drug-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Fingolimod Hydrochloride; Hepatitis E; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis | 2017 |
Hepatitis E masquerading as drug-induced liver injury.
Topics: Adult; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Fingolimod Hydrochloride; Hepatitis E; Hepatitis E virus; Humans; Male; Multiple Sclerosis; Propylene Glycols; RNA, Viral; Sphingosine | 2012 |
Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice.
Topics: Animals; Chemical and Drug Induced Liver Injury; Concanavalin A; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Liver; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sulfhydryl Compounds; Treatment Outcome | 2006 |